How has Arcus Biosciences's contract liabilities, non-current changed year-over-year?

Arcus Biosciences's contract liabilities, non-current decreased by 79.5% year-over-year, from $219M to $45M.

What is the long-term trend for Arcus Biosciences's contract liabilities, non-current?

Over 5 years (2020 to 2025), Arcus Biosciences's contract liabilities, non-current has grown at a -20.2% compound annual growth rate (CAGR), from $132.53M to $43M.

Arcus Biosciences RCUS Contract Liabilities, Non-Current

Contract Liabilities, Non-Current at other companies

Regeneron PharmaceuticalsREGN

——

ExelixisEXEL

——

Kymera TherapeuticsKYMR

——

Other financials

Income statement

See full

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

See full

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total equity$524.0M-1.3%

Total assets$997.0M-13.8%

Cash flow

See full

Operating cash flow-$138.0M-4.5%

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation

See full

Market cap$3.62B+226%

Enterprise value$3.53B+275%

P/S15.4×+7.5×

Profitability

See full

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

See full

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's contract liabilities, non-current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arcus Biosciences's contract liabilities, non-current?: Arcus Biosciences (RCUS) reported contract liabilities, non-current of $45M in Q1 2026.
How has Arcus Biosciences's contract liabilities, non-current changed year-over-year?: Arcus Biosciences's contract liabilities, non-current decreased by 79.5% year-over-year, from $219M to $45M.
What is the long-term trend for Arcus Biosciences's contract liabilities, non-current?: Over 5 years (2020 to 2025), Arcus Biosciences's contract liabilities, non-current has grown at a -20.2% compound annual growth rate (CAGR), from $132.53M to $43M.